Clinical trials: Resistant Depression, Treatment
Major Depressive Disorder
Treatment Resistant Geriatric Depression in Primary Care
This study involves collaboration between McLean Hospital, Geriatric Medicine at the Cambridge Health Alliance (CHA) and other sites within the Partners and Harvard Medical School network.
- Trial name
- NCT01392287
- Testing
- Memantine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Treatment Resistant Depression, Major Depressive Disorder
pBFS Guided rTMS Over DMPFC for Treatment-Resistant Depression
Investigators aim to evaluate the safety and efficacy of pBFS-guided rTMS therapy targeting DMPFC for patients with treatment-resistant depression
- Trial name
- NCT05948839
- Testing
- active rTMS treatment
- Where
- 3 sites in China
- Volunteers
- 170 people
- Sponsor
- Changping Laboratory
Treatment-resistant Depression
Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression
Treatment resistant depression (TRD) is a frequent, debilitating condition mostly treated by antidepressants. Repeated magnetic transcranial stimulation (rTMS) has proven adjuvant efficacy in TRD in the acute phase of treatment…
- Trial name
- ACOUSTIM (NCT03701724)
- Testing
- Systematic maintenance rTMS, rTMS course in case of relapse
- Where
- 19 sites in France
- Volunteers
- 119 people
- Sponsor
- Nantes University Hospital
Borderline Personality Disorder
Magnetic Seizure Therapy for the Treatment of Borderline Personality Disorder
Suicide is a major public health crisis for which effective new interventions are needed. An innovative new brain stimulation technique called magnetic seizure therapy (MST) shows promise for treating suicidal thinking in…
- Trial name
- NCT03361826
- Testing
- MagPro MST with Cool TwinCoil, DBT
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- Centre for Addiction and Mental Health
Eye Movement Desensitization and Reprocessing, Cognitive Behavioral Therapy
RCT Comparing EMDR and CBT for Treatment of Resistant Depression
Depression is one of the most common invalidating mental disorders, ranked by World Health Organization as the single largest contributor to global disability.
- Conditions
- Eye Movement Desensitization and Reprocessing, Cognitive Behavioral Therapy, Neurobiological Processing, Depression
- Trial name
- NCT03972033
- Testing
- EMDR, CBT
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- University of Turin, Italy
Treatment-Resistant Major Depressive Disorder
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
This open-label fMRI study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with treatment-resistant major depressive disorder.
- Trial name
- NCT05381974
- Testing
- Psilocybin
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Depression, Major Depressive Disorder
pBFS-guided High-dose TMS Over DMPFC for Treatment-resistant Major Depressive Disorder
The investigators aim to evaluate the safety and efficacy of pBFS-guided DMPFC target and high-dose rTMS therapy for the treatment of patients with treatment-resistant depression
- Conditions
- Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT05964036
- Testing
- active TMS
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Changping Laboratory
Treatment-resistant Depression
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).
- Trial name
- SUSTAIN-2 (NCT02497287)
- Testing
- Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 109 sites in United States, Argentina and 19 more
- Volunteers
- 802 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression
Ketamine Frequency Treatment for Major Depressive Disorder
Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range…
- Trial name
- NCT00646087
- Testing
- Ketamine, Ketamine/Saline
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Essentia Health
Major Depressive Disorder
Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)
An open label study to assess the safety, tolerability, and effects of intranasal Ketamine in combination with rTMS for patients with treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT04352621
- Testing
- intranasal ketamine, rTMS treatment
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Treatment Resistant Major Depression Disorder
DBS of the Habenula for Treatment- Resistant Major Depression
The habenula(Hb) is an epithalamic structure located at the center of the dorsal diencephalic conduction system, a pathway involved in linking forebrain to midbrain regions.
- Trial name
- NCT03347487
- Testing
- Deep brain stimuation system implantation
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Ruijin Hospital
Major Depressive Disorder
An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression
The purpose of this study is to examine the potential impact of the assay in terms of depression severity as measured by change in Clinical Global Impressions (CGI) scale at 3 months.
- Trial name
- NCT01438242
- Testing
- Genecept Assay
- Where
- United States
- Sponsor
- Genomind, LLC
Depression
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT01204918
- Testing
- Riluzole
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Major Depressive Disorder, Treatment Resistant Depression
MAO-B Occupancy in Depressed Patients
The study is looking at assessing monoamine oxidase B (MAO-B) occupancy in depressed patients before and after medication treatment using positron emission tomography (PET) scan.
- Trial name
- MOCP (NCT04841798)
- Testing
- [11C]SL25.1188 PET radiotracer
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depression
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
The investigators plan to use optical brain imaging technology to observe patients with current major depression before, during, and after repetitive Transcranial Magnetic Stimulation (rTMS) clinical treatment.
- Trial name
- NCT01768052
- Testing
- functional Near Infrared Spectroscopy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder, Suicide
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years).
- Conditions
- Major Depressive Disorder, Suicide, Treatment Resistant Depression
- Trial name
- Ket-CBT (NCT06480500)
- Testing
- Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Major Depressive Disorder
Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study
number of center : 1 duration of study : 24 months recruitement time : 23 months Aim :Principal Evaluate the interest of maintenance rTMS in a one-year double blind randomized controlled study for TRD patients.
- Trial name
- TMS/DEP (NCT02383693)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Depressive Disorder, Treatment-Resistant
e-PAT Neuromod Evaluation of Personalized rTMS for Resistant Depression
Although repetitive trans-cranial magnetic stimulation (rTMS) is an effective therapy for resistant depression, it still fail to remit up to 70% of these patients.
- Trial name
- NCT02410421
- Testing
- Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning
- Sponsor
- University Hospital, Strasbourg, France
Treatment Resistant Depression
COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression
The CoMPACT trial is a randomized double-blinded sham-controlled study aimed at testing a novel accelerated and personalized transcranial Magnetic Stimulation (TMS) treatment for patients with Treatment Resistant Depression…
- Trial name
- CoMPACT (NCT06895863)
- Testing
- MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil., Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil.
- Where
- 3 sites in Denmark
- Volunteers
- 78 people
- Sponsor
- Danish Research Centre for Magnetic Resonance
Treatment-Resistant Major Depressive Disorder
Avatar Therapy in Virtual Reality for Treatment-Resistant Major Depressive Disorder: A Pilot Study
This pilot clinical trial aimed to evaluate the short-term efficacy of Avatar therapy for treatment-resistant major depressive disorder
- Trial name
- NCT07112261
- Testing
- Avatar Therapy
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal